The management of opportunistic infections in the era of highly active antiretroviral therapy

AIDS Reviews

Volumn 2, Issue 4, 2000, Pages 252-262

  Ferrer, E ^a   Podzamczer, D ^a  

^a Universitaria de Bellvitge   (Spain)

Author keywords

HAART; Opportunistic infections; Prophylaxis

Indexed keywords

ACICLOVIR; AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DAPSONE; FLUCONAZOLE; FOLINIC ACID; FOSCARNET; GANCICLOVIR; HEPATITIS B VACCINE; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; MEGLUMINE ANTIMONATE; MICONAZOLE; NYSTATIN; PENTAMIDINE; PYRAZINAMIDE; PYRIMETHAMINE; RIFABUTIN; RIFAMPICIN; RITONAVIR; SAQUINAVIR; SULFADIAZINE; UNINDEXED DRUG; VACCINE;

ANTIBIOTIC PROPHYLAXIS; BACTERIAL INFECTION; CELL COUNT; CYTOMEGALOVIRUS INFECTION; DRUG POTENCY; HEALTH CARE MANAGEMENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNITY; INFECTION RISK; LYMPHOCYTE COUNT; MYCOSIS; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; QUALITY OF LIFE; RETINITIS; REVIEW; RISK MANAGEMENT; T LYMPHOCYTE; TOXICITY; TOXOPLASMOSIS; VIRUS INFECTION; VIRUS LOAD;

EID: 0034448670     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (98)

1. Recent advances in the management of AIDS-related opportunistic infections
2. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: Evidence of a new acquired cellular immunodeficiency
3. An outbreak of community acquired Pneumocystis carinii pneumonia: Initial manifestation of cellular immune dysfunction
4. Guidelines for prophylaxis against Pneumocystis carinii pneumonia for persons infected with human immunodeficiency virus
5. 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus
6. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus
7. Intermittent trimethoprim-sulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmosis in patients infected with HIV
8. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: An international randomized trial: Terry Beirn Community Programs for Clinical Research on AIDS
9. Oral Ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS
10. Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection
11. Public Health Service Task Force on prophylaxis and therapy for Mycobacterium avium complex disease in patients infected with human immunodeficiency virus
12. Decline in CMV and other opportunistic disease with combination antiretroviral therapy
13. Relations among CD4 lymphocyte count nadir, antiretroviral therapy and HIV-1 disease progression: Results from the EuroSIDA study
14. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
15. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less, AIDS Clinical Trials Group 320 Study Team
16. Immunologic effects of combined protease inhibitor and reverse transcriptase inhibitor therapy in previously treated chronic HIV-1 infection
17. Alterations in the immune response of human immunodeficiency virus infected subjects treated with an HIV specific protease inhibitor, ritonavir
18. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease
19. Vigorous HIV-1 specific CD4+T cell responses associated with control of viremia
20. Surveillance for AIDS-defining opportunistic illnesses, 1992-1997
21. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group
22. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres
23. Immune recovery vitritis associated with inactive cytomegalovirus retinitis: A new syndrome
24. Transient vitreous inflammatory reactions associated with combination antiretroviral therapy in patients with AIDS and cytomegalovirus retinitis
25. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease
26. Paradoxical reactions in HIV and pulmonary TB
27. Effects of HAART on natural history of AIDS-related opportunistic infections
28. Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy
29. AIDS diagnoses at higher CD4 counts in Australia following the introduction of highly active antiretroviral treatment
30. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients
31. Analysis of the discontinuation of protease inhibitor therapy in routine clinical practice
32. Opportunistic infections. Report from the 7th Conference on Retroviruses and Opportunistic Infections. Newsline
33. Serial CD4 lymphocyte counts and development of AIDS
34. Predictors of rapid progression to AIDS in HIV-1 seroconverters
35. USPHS/IDSA Guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: An overview
36. Prognosis in HIV infection predicted by the quantity of virus in plasma
37. Plasma HIV viral load in patients with hemophilia and late-stage HIV disease: A measure of current immune suppression: Multicenter Hemophilia Cohort Study
38. Prognostic value of plasma HIV RNA in the natural history of pneumocystis carinii pneumonia, cytomegalovirus and Mycobacterium avium complex
39. HIV plasma RNA, an independent predictor of opportunistic infections in HIV-infected persons
40. Predictive value of CD4 lymphocyte numbers for the development of opportunistic infections and malignancies in HIV-infected persons
41. The risk of Pneumocystis carinii pneumonia
42. Linfocitos CD4+ e infecciones oportunistas y neoplasias en pacientes con infección por VIH
43. Natural history of opportunistic disease in an HIV-infected urban clinic cohort
44. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation
45. Restauración inmunológica y tratamiento antirretroviral de gran actividad (TARGA)
46. HIV infection induces changes in CD4+ cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies
47. Perturbation of CD4+ and CD8+ T-cell repertoires during progression to AIDS and regulation of the CD4+ repertoire during antiviral therapy
48. Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus infected patients
49. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection
50. Dapsonepyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection
51. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection
52. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both
53. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS
54. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection
55. Profilaxis primaria y secundaria de las infecciones más frecuentes e inmunización en pacientes adultos con infección por VIH
56. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis
57. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus
58. Anergy skin testing and preventive therapy for HIV-infected persons: Revised recommendations
59. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection
60. Prevention and treatment of tuberculosis among patients infected human immunodeficiency virus: Principles of therapy and revised recommendations
61. Randomised trial of isoniazid versus rifampicin and pirazinamide for prevention of tuberculosis in HIV-1 infection
62. Guidelines for the use of Rifabutin or Rifampin for the Treatment and Prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors
63. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex in AIDS
64. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome
65. PCR of plasma for cytomegalovirus DNA identifies HIV-infected persons most likely to benefit from oral ganciclovir prophylaxis
66. pp65 antigenemia as a marker of future CMV disease and mortality in HIV-infected patients
67. Fluconazole-resistant Candida albicans after long-term suppressive therapy
68. Leishmania and human immunodeficiency virus coinfection: The first 10 years
69. Pneumococcal vaccination and the incidence of pneumonia among HIV-infected persons
70. Efficacy of influenza vaccination in HIV-infected persons: A randomized, double-blind, placebo-controlled trial
71. Pyrimethamine-clindamycin versus pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS
72. Thrice-weekly sulfadiazine-pyrimethamine for maintenance therapy of toxoplasmic encephalitis in HIV-infected patients
73. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS
74. Intravenous versus oral ganciclovir: European/Australian comparative study of efficacy and safety in the prevention of cytomegalovirus retinitis recurrence in patients with AIDS
75. A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome
76. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease: A randomized, double-blind, dose-ranging study in patients with AIDS
77. Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients
78. A randomized trial of daily and thrice-weekly trimethoprim-sulfamethoxazole for the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected persons: Terry Beirn Community Programs for Clinical Research on AIDS
79. Atovaquone compared for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both
80. Valganciclovir (VGCV) vs. IV ganciclovir (GCV) as induction therapy for newly diagnosed cytomegalovirus (CMV) retinitis: A randomized controlled study
81. A multicenter randomized trial comparing amphotericin B (AmB) and liposomal Amphotericin B (AmBisome, LamB) as induction therapy of disseminated histoplasmosis (DH) in AIDS patients
82. Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy
83. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy
84. Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1 infected patients treated with highly active antiretroviral therapy
85. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection
86. Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy?
87. Discontinuation of PCP prophylaxis is safe in HIV-infected patients after immunological recovery with HAART: Results of the Gesida 04/98 study
88. The risk for Pneumocystis carinii pneumonia (PCP) and disseminated non-tuberculous mycobacteriosis (dMb) after an antiretroviral therapy (ART) associated increase in the CD4+ T-lymphocyte count
89. It is safe to discontinue secondary prophylaxis for PCP in HIV-infected patients treated with HAART: Results from eight prospective European cohorts
90. Discontinuation of primary or secondary Toxoplasma gondii prophylaxis is safe in HIV-1-infected patients after immunological recovery with HAART: Final results of the GESIDA 04/98-B study
91. Stopping primary prophylaxis in HIV-1-infected patients at high risk of toxoplasma encephalitis
92. Discontinuation of anticytomegalovirus therapy in persons with HIV infection and cytomegalovirus retinitis
93. Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy
94. Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients
95. Discontinuation of maintenance therapy in patients with quiescent cytomegalovirus retinitis and elevated CD4+ counts
96. Absence of reactivation of cytomegalovirus (CMV) retinitis after discontinuation of CMV maintenance therapy in patients on HAART
97. Discontinuation of prophylaxis against Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. Terry Beirn Community Programs for Clinical Research on AIDS
98. Discontinuation of antifungal therapy for cryptococcosis after immunologic response to antiretroviral therapy